Article ID Journal Published Year Pages File Type
8615441 Clinical Lymphoma Myeloma and Leukemia 2018 88 Pages PDF
Abstract
Our study found that the combination of GO with azacitidine is relatively well tolerated, with response rates similar to those with GO monotherapy at higher doses. Differences in the GO drug schedule, dose level, and frequency might explain the discrepant response rates between our study and others, suggesting that the optimal GO dose remains unclear, especially when combined with hypomethylating agent therapy.
Related Topics
Health Sciences Medicine and Dentistry Anesthesiology and Pain Medicine
Authors
, , , , , , , ,